Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) General Counsel & COO, Robert Ticktin, sold 23,151 shares of common stock on July 1, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $1.0648, for a total transaction value of $24,651.
The sale was to satisfy tax obligations related to the vesting of restricted stock units. Following the transaction, Ticktin directly owns 98,695 shares of PMV Pharmaceuticals, Inc. This includes 15,528 shares acquired under the Issuer’s Employee Stock Purchase Plan on May 15, 2025. With a market capitalization of $61.82 million, PMVP shows promising signs with strong returns over recent months. InvestingPro subscribers have access to 13 additional investment tips for PMVP.
In other recent news, PMV Pharmaceuticals held its virtual 2025 Annual Meeting of Stockholders, where several key proposals were voted on by the stockholders. During the meeting, Arnold Levine, Ph.D., and Charles M. Baum, M.D., Ph.D., were elected as Class II Directors, set to serve until the 2028 annual meeting. The election saw Levine receiving 26,723,192 votes in favor, while Baum received 13,258,337 votes in favor. A non-binding advisory vote on the compensation of the company’s named executive officers was also conducted but did not pass, with 20,170,398 votes against it. Additionally, the stockholders ratified the selection of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal was approved with 39,963,653 votes in favor. These developments were reported in a press release statement filed with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.